The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Confidence In A Treatment You Can Manage1-6
To help you prevent, identify and manage possible Adverse Events (AEs) with IBRANCE®, select an AE from the list below for useful management tips for both you and your patients†.
Get plenty of rest; patients should try to sleep at least 8 hours each night and might also want to take 1–2 short naps (1 hour or less) during the day8
Avoid medications that interfere with platelets being able to form clots e.g. NSAIDs8
Including an anti-infective for bacterial infections as appropriate.1
Avoid crowded places, and do not visit people with infections, coughs, or fevers7
If necessary, nausea and vomiting can be treated with an anti-emetic as appropriate.7
† Preferred terms (PTs) are listed according to MedDRA 17.1.
INFECTIONS includes all PTs that are part of the System Organ Class Infections and infestations.
NEUTROPENIA includes the following PTs: Neutropenia; Neutrophil count decreased.
LEUKOPENIA includes the following PTs: Leukopenia; White blood cell count decreased.
ANAEMIA includes the following PTs: Anaemia, Haemoglobin decreased, Haematocrit decreased.
THROMBOCYTOPENIA includes the following PTs: Thrombocytopenia, Platelet count decreased.
STOMATITIS includes the following PTs: Aphthous stomatitis, Cheilitis, Glossitis, Glossodynia, Mouth ulceration, Mucosa! inflammation, Oral pain, Oropharyngeal discomfort, Oropharyngeal pain, Stomatitis.
RASH includes the following PTs: Rash, Rash maculo-papular, Rash pruritic, Rash erythematous, Rash papular, Dermatitis, Dermatitis acneiform, Toxic skin eruption1
For the most up-to-date safety information, please refer to the full IBRANCE® Summary of Product Characteristics.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
IBRANCE® safety information and outcomes
Efficacy results for IBRANCE®
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020